Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors

Author:

Kantarjian Hagop M.1,Cortes Jorge E.1,Kim Dong-Wook2,Khoury H. Jean3,Brümmendorf Tim H.45,Porkka Kimmo6,Martinelli Giovanni7,Durrant Simon8,Leip Eric9,Kelly Virginia10,Turnbull Kathleen11,Besson Nadine12,Gambacorti-Passerini Carlo13

Affiliation:

1. Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX;

2. Department of Hematology, Seoul St. Mary’s Hospital, Seoul, South Korea;

3. Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA;

4. Hematology, Oncology, and Stem Cell Transplantation, Universitätsklinikum Aachen, Rheinisch-Westfaelische Technische Hochschule Aachen, Aachen, Germany;

5. Hematology, Oncology, and Stem Cell Transplantation, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany;

6. Division of Hematology, Helsinki University Central Hospital, Helsinki, Finland;

7. Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy;

8. Bone Marrow Transplant Unit, Royal Brisbane Hospital, Herston, Australia;

9. Oncology Clinical Statistics,

10. Oncology Clinical Research, and

11. Oncology Clinical Development, Pfizer Inc., Cambridge, MA;

12. Pfizer Global Research and Development, Paris, France; and

13. Clinical Research Unit, University of Milano-Bicocca, Monza, Italy

Abstract

Key Points Bosutinib had manageable toxicity and acceptable tolerability, with adverse events distinct from that of other tyrosine kinase inhibitors. Adverse events were primarily characterized by early-onset gastrointestinal events that were low grade, transient, and manageable.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Reference21 articles.

1. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.;Baccarani;Blood,2013

2. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology™. Chronic Myelogenous Leukemia. Version 1. 2014. Available at: http://www.nccn.org/professionals/physician_gls/pdf/cml.pdf. Accessed October 3, 2013

3. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology™. Acute Lymphoblastic Leukemia. Version 1. 2013. Available at: http://www.nccn.org/professionals/physician_gls/pdf/all.pdf. Accessed October 3, 2013

4. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.;O’Brien;N Engl J Med,2003

5. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.;de Lavallade;J Clin Oncol,2008

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3